Reference : Ph Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2...
Scientific congresses and symposiums : Paper published in a journal
Human health sciences : Oncology
http://hdl.handle.net/2268/157167
Ph Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2+ advanced breast cancer
English
Pistilli, Barbara [Macerata Hospital, Macerata, Italy > > > >]
Urruticoechea, Ander [Catalan Institute of Oncology, Barcelona, Spain > > > >]
Chan Stephen [Nottingham University Hospital, Nottingham, UK > > > >]
Han, Hyo Sook [Moffit Cancer Center, Tampa, FL > > > >]
JERUSALEM, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Kong, Anthony [Oxford University Hospitals NHS Trust, Oxford, UK > > > >]
Ru, Qinhua [Novartis Oncology, Florham Park, NJ > > > >]
Ruquet, Sophie [Novartis Oncology, Paris, France > > > >]
Sternberg, David [Novartis Oncology, Florham Park, NJ > > > >]
Saura, Cristina [Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain > > > >]
2012
Annals of Oncology
Oxford University Press
23
supplément 9
ix116
Yes (verified by ORBi)
International
0923-7534
1569-8041
London
United Kingdom
37th ESMO Congress
28 September - 2 October 2012
ESMO
Vienna
Austria
http://hdl.handle.net/2268/157167

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
ESMO 2012 abstract.pdfPublisher postprint7.14 MBRequest copy

Additional material(s):

File Commentary Size Access
Restricted access
ESMO 2012 - présentation.pdf444.76 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.